Targeting hypoxia in cancer therapy

Area of Science:

• Oncology
• Cancer Biology
• Translational Medicine

Background:

• Hypoxia, or low oxygen, is prevalent in most tumors and significantly impacts patient prognosis.
• Tumor hypoxia contributes to chemoresistance, radioresistance, angiogenesis, invasiveness, metastasis, and altered metabolism, making it a critical factor in cancer progression and therapeutic failure.

Purpose of the Study:

• To review current strategies for targeting tumor hypoxia in oncology.
• To discuss the challenges and opportunities associated with exploiting tumor hypoxia as a therapeutic target.
• To highlight the role of emerging diagnostic tools in patient stratification for hypoxia-targeted therapies.

Main Methods:

• Review of scientific literature on tumor hypoxia and its therapeutic targeting.
• Analysis of two primary approaches: bioreductive prodrugs and inhibitors of molecular targets crucial for hypoxic cell survival.
• Discussion of diagnostic tools for patient stratification.

Main Results:

• Hypoxia is a validated but underexploited target in oncology due to its multifaceted role in tumor progression and resistance.
• Bioreductive prodrugs and molecular inhibitors represent key strategies for exploiting tumor hypoxia.
• Emerging diagnostic tools are crucial for identifying patients who will benefit from hypoxia-targeted therapies.

Conclusions:

• Targeting tumor hypoxia is a critical unmet need in oncology.
• A combination of therapeutic strategies and advanced diagnostics is essential for successful clinical translation.
• Further research is needed to overcome challenges and fully realize the therapeutic potential of targeting tumor hypoxia.